ME02434B - Nova jedinjenja koja moduliraju fxr (nr1h4) - Google Patents

Nova jedinjenja koja moduliraju fxr (nr1h4)

Info

Publication number
ME02434B
ME02434B MEP-2016-81A MEP201681A ME02434B ME 02434 B ME02434 B ME 02434B ME P201681 A MEP201681 A ME P201681A ME 02434 B ME02434 B ME 02434B
Authority
ME
Montenegro
Prior art keywords
liver
alkyl
compound according
group
disease
Prior art date
Application number
MEP-2016-81A
Other languages
German (de)
English (en)
French (fr)
Inventor
Olaf Kinzel
Christoph Steeneck
Claus Kremoser
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of ME02434B publication Critical patent/ME02434B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Claims (17)

1. Jedinjenje prema sledećoj formuli (1), njegov enantiomer, diastereomer, tautomer ili farmaceutski prihvatljiva so u komeR je izabran iz grupe koja se sastoji od COOR6, CONR7R8, tetrazolil, SO2NR7R8, C1-6 alkil, SO2-C1-6 alkil i H, pri čemu je R6 nezavisno izabran iz grupe koja se sastoji od H ili C1-6alkil, i R7 i R8 međusobno nezavisno su izabrani iz grupe koja se sastoji od H, C1-6alkil, halo-C1-6 alkil, C1-6 alkilen-R9, SO2-C1-6, alkil, gde je R9 izabran iz grupe koja se sastoji od COOH, OH i SO3H;A je izabran iz grupe koja se sastoji od: fenil, piridil, pirimidil, pirazolil, indolil, tienil, benzotienil, indazolil, benzizoksazolil, benzofuranil, benzotriazolil, furanil, benzotiazolil, tiazolil, oksadiazolil, svaki izborno supstituisan sa jednom ili dve grupe nezavisno izabrane iz grupe koja se sastoji od OH, O-C1-6 alkil, O-halo-C1-6 alkil, alkil, halo-C1-6 alkil, C3-6 cikloalkil i halogen;Q je izabran iz grupe koja se sastoji od fenil, piridil, tiazolil, tiofenil, pirimidil, svaka izborno supstituisana sa jednom ili dvegrupe nezavisno izabrane iz grupe koja se sastoji od C1-6alkil, halo-C1-6 alkil, halogen i CF3;Y je izabran od N ili CH;Z je izabran od ili u komeX = CH, N, NO;R1 je izabran iz grupe koja se sastoji od vodonika, C1-3 alkil, C3-6 cikloalkil, C4-5 alkilcikloalkil, gde je C1-3 alkil izborno supstituisan sa 1 do 3 supstituenta nezavisno izabrana od halogena, hidroksi ili C1-6alkoksi;R2 i R3 su nezavisno izabrani iz grupe koja se sastoji od vodonika, C1-3 alkil, C1-3 haloalkil, C1-3 alkoksi, C1-3 haloalkoksi i halogen.
2. Jedinjenje prema patentnom zahtevu 1 naznačeno time što R-A je izabran od ili
3. Jedinjenje prema patentnom zahtevu 1 ili 2 naznačeno time što Q je
4. Jedinjenje prema bilo kom od patentnih zahteva 1 do 3 naznačeno time što Z je
5. Jedinjenje prema bilo kom od patentnih zahteva 1 do 4 izabrano od ili ili njegova farmaceutski prihvatljiva so.
6. Jedinjenje prema bilo kom od patentnih zahteva 1 do 5 koje ima sledeću strukturu ili njegova farmaceutski prihvatljiva so.
7. Jedinjenje prema bilo kom od patentnih zahteva 1 do 5 koje ima sledeću strukturu ili njegova farmaceutski prihvatljiva so.
8. Farmaceutska kompozicija koja sadrži jedinjenje prema bilo kom od patentnih zahteva 1 do 7, ili njegovu farmaceutski prihvatljivu so, i farmaceutski prihvatljiv nosač.
9. Jedinjenje prema bilo kom od patentnih zahteva 1 do 7 za upotrebu kao lek.
10. Jedinjenje prema bilo kom od patentnih zahteva 1 do 7 za upotrebu u profilaksi i/ili lečenju bolesti posredovanih preko FXR.
11. Jedinjenje za upotrebu prema patentnom zahtevu 10 naznačeno time što je bolest izabrana od hroničnog intrahepatičnog ili izvesnih oblika ekstrahepatičnih holestatičkih stanja; fibroze jetre; opstruktivnih ili hroničnih inflamatornih poremećaja jetre; ciroze jetre; steatoze jetre i srodnih sindroma, holestatičkih ili fibrotičkih efekata koji su povezani sa cirozom koja je indukovana alkoholom ili sa virusnim oblicima hepatitisa; insuficijencije jetre ili ishemije jetre posle velike resekcije jetre; steatohepatitisa povezanog sa hemoterapijom (CASH); akutne insuficijencije jetre; i/ili inflamatornih bolesti creva.
12. Jedinjenje za upotrebu prema patentnom zahtevu 10 naznačeno time što je bolest izabrana od poremećaja lipida i lipoproteina; dijabetesa tipa II i kliničkih komplikacija dijabetesa tipa I i tipa II, uključujući dijabetičku nefropatiju, dijabetičku neuropatiju, dijabetičku retinopatiju i druge zabeležene efekte kliničke manifestacije dugotrajnog dijabetesa; stanja i bolesti koja su rezultat hronične masne i fibrotičke degeneracije organa kao posledica pojačane akumulacije lipida i naročito triglicerida i kasnije aktivacije profibrotičkih puteva, kao što je bolest nealkoholne masne jetre (NAFLD) ili nealkoholni steatohepatitis (NASH); gojaznosti ili metaboličkog sindroma (kombinovana stanja dislipidemije, dijabetesa ili abnormalno visokog indeksa telesne mase); i/ili akutnog infarkta miokarda, akutnog šloga ili tromboze koji se javlja kao krajnja tačka hronične opstruktivne ateroskleroze.
13. Jedinjenje za upotrebu prema patentnom zahtevu 10 naznačeno time što je bolest izabrana od nemalignih hiperproliferativnih poremećaja i malignih hiperproliferativnih poremećaja, naročito hepatoćelijskog karcinoma, adenoma debelog creva i polipoza, adenokarcinoma debelog creva, kancera dojke, adenokarcinoma pankreasa, Baretovog jednjaka ili drugih oblika neoplastičnih bolesti gastrointestinalnog trakta i jetre.
14. Upotreba jedinjenja prema bilo kom od patentnih zahteva 1 do 7 za pripremu leka za profilaksu i/ili lečenje bolesti posredovanih preko FXR.
15. Upotreba prema patentnom zahtevu 14 naznačena time što je bolest izabrana od hroničnih intrahepatičnih ili izvesnih oblika ekstrahepatičnih holestatičkih stanja; fibroze jetre; opstruktivnih ili hroničnih inflamatornih poremećaja jetre; ciroze jetre; steatoze jetre i povezanih sindroma, holestatičkih ili fibrotičkih efekata koji su povezani sa cirozom koja je indukovana alkoholom ili sa virusnim oblicima hepatitisa; insuficijencije jetre ili ishemije jetre posle velike resekcije jetre; steatohepatitisa povezanog sa hemoterapijom (CASH); akutne insuficijencije jetre; i/ili inflamatornih bolesti creva.
16. Upotreba prema patentnom zahtevu 14 naznačena time što je bolest izabrana od poremećaja lipida i lipoproteina; dijabetesa tipa II i kliničkih komplikacija dijabetesa tipa I i tipa II, uključujući dijabetičku nefropatiju, dijabetičku neuropatiju, dijabetičku retinopatiju i druge zabeležene efekte kliničke manifestacije dugotrajnog dijabetesa; stanja i bolesti koji su rezultat hronične masne i fibrotičke degeneracije organa kao posledica pojačane akumulacije lipida i naročito triglicerida i kasnije aktivacije profibrotičkih puteva; kao što je bolest nealkoholne masne jetre (NAFLD) ili nealkoholni steatohepatitis (NASH); gojaznosti ili metaboličkog sindroma (kombinovana stanja dislipidemije, dijabetesa ili abnormalno visokog indeksa telesne mase); i/ili akutnog infarkta miokarda, akutnog šloga ili tromboze koja se javlja kao krajnja tačka hronične opstruktivne ateroskleroze.
17. Upotreba prema patentnom zahtevu 14 naznačena time što je bolest izabrana od nemalignih hiperproliferativnih poremećaja i malignih hiperproliferativnih poremećaja, naročito hepatoćelijskog karcinoma, adenoma debelog creva i polipoza, adenokarcinoma debelog creva, kancera dojke, adenokarcinoma pankreasa, Baretovog jednjaka ili drugih oblika neoplastičnih bolesti gastrointestinalnog trakta i jetre.
MEP-2016-81A 2011-07-13 2012-07-12 Nova jedinjenja koja moduliraju fxr (nr1h4) ME02434B (me)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161507153P 2011-07-13 2011-07-13
EP11005722A EP2545964A1 (en) 2011-07-13 2011-07-13 Novel FXR (NR1H4) binding and activity modulating compounds
PCT/EP2012/002941 WO2013007387A1 (en) 2011-07-13 2012-07-12 Novel fxr (nr1h4) binding and activity modulating compounds
EP12735100.5A EP2731676B1 (en) 2011-07-13 2012-07-12 Novel fxr (nr1h4) modulating compounds

Publications (1)

Publication Number Publication Date
ME02434B true ME02434B (me) 2016-09-20

Family

ID=44513243

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2016-81A ME02434B (me) 2011-07-13 2012-07-12 Nova jedinjenja koja moduliraju fxr (nr1h4)

Country Status (31)

Country Link
US (5) US9139539B2 (me)
EP (5) EP2545964A1 (me)
JP (2) JP5986633B2 (me)
KR (4) KR101722410B1 (me)
CN (2) CN103702719B (me)
AR (1) AR087127A1 (me)
AU (4) AU2012283387C1 (me)
BR (3) BR112014000260B1 (me)
CA (1) CA2839357C (me)
CY (1) CY1117453T1 (me)
DK (2) DK3246070T3 (me)
EA (1) EA024843B1 (me)
ES (3) ES2569718T3 (me)
FI (1) FI3246070T3 (me)
HR (2) HRP20240422T1 (me)
HU (2) HUE027931T2 (me)
IL (1) IL229944A (me)
LT (1) LT3246070T (me)
ME (1) ME02434B (me)
MX (2) MX368371B (me)
MY (1) MY161158A (me)
PH (1) PH12014500124A1 (me)
PL (3) PL2987532T3 (me)
PT (2) PT2987532T (me)
RS (1) RS54786B1 (me)
SI (3) SI2987532T1 (me)
SM (1) SMT201600169B (me)
TW (1) TWI439455B (me)
UY (1) UY34196A (me)
WO (1) WO2013007387A1 (me)
ZA (1) ZA201309521B (me)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI598347B (zh) 2009-07-13 2017-09-11 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
IL253437A0 (en) * 2011-07-13 2017-09-28 Gilead Sciences Inc New compounds modulate fxr (nr1h4) activity and bind
SI3043865T1 (sl) 2013-09-11 2021-04-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Metode in farmacevtski sestavki za zdravljenje virusne okužbe s hepatitisom B
MX2017003933A (es) 2014-09-24 2017-06-30 Gilead Sciences Inc Metodos de tratamiento de la enfermedad hepatica.
EP3006939A1 (en) 2014-10-06 2016-04-13 Gilead Sciences, Inc. Histidine-rich Glycoprotein as a marker for hepatic Farnesoid X receptor activation
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
EP3034499A1 (en) * 2014-12-17 2016-06-22 Gilead Sciences, Inc. Novel FXR (NR1H4) modulating compounds
EP3034501A1 (en) * 2014-12-17 2016-06-22 Gilead Sciences, Inc. Hydroxy containing FXR (NR1H4) modulating compounds
US20170368038A1 (en) * 2014-12-18 2017-12-28 Novartis Ag Azabicyclooctane derivatives as fxr agonists for use in the treatment of liver and gastrointestinal diseases
CN112225699B (zh) 2014-12-23 2023-11-14 吉利德科学公司 制备ask1抑制剂的方法
MA41252A (fr) 2014-12-23 2017-10-31 Gilead Sciences Inc Formes solides d'un inhibiteur d'ask 1
TWI698430B (zh) 2015-02-13 2020-07-11 南北兄弟藥業投資有限公司 三環化合物及其在藥物中的應用
CA2981503C (en) 2015-03-31 2023-09-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
PL3456717T3 (pl) 2015-07-06 2021-10-25 Gilead Sciences, Inc. Pochodna 4,6-diaminochinolino-3-karbonitrylu jako modulator cot (cancer osaka thyroid) do leczenia choroby zapalnej
CN106995416A (zh) * 2016-01-26 2017-08-01 上海翰森生物医药科技有限公司 Fxr激动剂及其制备方法和应用
WO2017128896A1 (zh) * 2016-01-26 2017-08-03 江苏豪森药业集团有限公司 Fxr激动剂及其制备方法和应用
TW201741307A (zh) * 2016-02-22 2017-12-01 艾洛斯生物製藥公司 Ｆｘｒ調節劑及其使用方法
AU2017228371A1 (en) 2016-03-04 2018-09-13 Gilead Sciences, Inc. Compositions and combinations of autotaxin inhibitors
EP3440113A1 (en) 2016-04-08 2019-02-13 Gilead Sciences, Inc. Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
WO2017189663A1 (en) * 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
US10080741B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
WO2017189651A1 (en) * 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
US10144729B2 (en) 2016-05-18 2018-12-04 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
WO2017201152A1 (en) 2016-05-18 2017-11-23 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
WO2017201155A1 (en) 2016-05-18 2017-11-23 Enanta Pharmaceuticals, Inc. lSOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF
NZ748641A (en) 2016-06-13 2020-04-24 Gilead Sciences Inc Fxr (nr1h4) modulating compounds
AR108711A1 (es) * 2016-06-13 2018-09-19 Gilead Sciences Inc Compuestos moduladores de fxr (nr1h4)
CA2968836C (en) * 2016-06-13 2025-09-02 Gilead Sciences, Inc. FXR MODULATING COMPOUNDS (NR1H4)
TW201808283A (zh) 2016-08-05 2018-03-16 廣東東陽光藥業有限公司 含氮三環化合物及其在藥物中的應用
CN106237332A (zh) * 2016-08-11 2016-12-21 河南大学 核受体fxr在肝癌干细胞靶向治疗中的应用
MX2019003790A (es) 2016-10-04 2019-09-26 Enanta Pharm Inc Analogos de isoxazol como agonistas de fxr y metodos de uso de los mismos.
CN107973790A (zh) * 2016-10-22 2018-05-01 合帕吉恩治疗公司 杂环fxr调节剂
WO2018081285A1 (en) * 2016-10-26 2018-05-03 Enanta Pharmaceuticals, Inc. Urea-containing isoxazole derivatives as fxr agonists and methods of use thereof
CA3042398A1 (en) * 2016-11-11 2018-05-17 Gilead Sciences, Inc. Methods of treating liver disease
CN106588804B (zh) * 2016-12-09 2018-11-09 都创(上海)医药科技有限公司 一种作为类法尼醇x受体(fxr)的化合物的制备方法
CN108218852A (zh) * 2016-12-15 2018-06-29 宁波百纳西药业有限公司 一种螺环化合物、其制备方法、组合物及用途
CN109071468B (zh) * 2017-01-20 2022-09-02 四川科伦博泰生物医药股份有限公司 一种杂环化合物及其制备方法和用途
JP7618384B2 (ja) 2017-02-21 2025-01-21 ジェンフィ Ｐｐａｒアゴニストとｆｘｒアゴニストとの組合せ
WO2018169742A1 (en) 2017-03-14 2018-09-20 Gilead Sciences, Inc. Apoptosis signal-regulating kinase inhibtor
SI4122464T1 (sl) * 2017-03-28 2024-07-31 Gilead Sciences, Inc. Terapevtske kombinacije za zdravljenje bolezni jeter
WO2018178260A1 (en) 2017-03-30 2018-10-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses
CA3058754A1 (en) 2017-04-07 2018-10-11 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonyl carbamate bile acid derivatives
JP2020516627A (ja) * 2017-04-12 2020-06-11 ギリアード サイエンシーズ， インコーポレイテッド 肝疾患を処置する方法
MX394743B (es) 2017-04-12 2025-03-04 Il Dong Pharma Derivados de isoxazol como agonistas del receptor nuclear y usos de los mismos
US10495648B2 (en) 2017-06-13 2019-12-03 Gilead Sciences, Inc. Methods of treating liver fibrosis
US10980810B2 (en) 2017-10-06 2021-04-20 Gilead Sciences, Inc. Combination therapy comprising an ACC inhibitor
JP7264906B2 (ja) 2017-11-01 2023-04-25 ブリストル－マイヤーズ スクイブ カンパニー ファルネソイドｘ受容体モジュレーターとしてのアルケン化合物
CA3081424A1 (en) 2017-11-01 2019-05-09 Bristol-Myers Squibb Company Spirocyclic compounds as farnesoid x receptor modulators
PE20201170A1 (es) 2017-11-01 2020-10-28 Bristol Myers Squibb Co Compuestos biciclicos en puente como moduladores del receptor farnesoide x
CN111278817B (zh) 2017-11-01 2023-05-16 百时美施贵宝公司 作为法尼醇x受体调节剂的多环化合物
CN111630051B (zh) 2017-11-01 2023-12-26 百时美施贵宝公司 作为法尼醇x受体调节剂的烯烃螺环化合物
EP3710599B1 (en) 2017-11-13 2024-07-17 Gilead Sciences, Inc. Method for staging liver fibrosis in nash patients
US10689391B2 (en) 2017-12-12 2020-06-23 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
CN110128432B (zh) 2018-02-02 2021-03-02 广东东阳光药业有限公司 含氮三环化合物及其在药物中的应用
WO2019160813A1 (en) 2018-02-14 2019-08-22 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
CN110818704B (zh) * 2018-08-08 2023-08-01 广州市恒诺康医药科技有限公司 螺桥环化合物、其药物组合物及其用途
ES2907187T3 (es) * 2018-08-08 2022-04-22 Inorbit Therapeutics Ab Compuestos útiles en la modulación del receptor de farnesoide X y métodos de fabricación y uso de los mismos
CN113056271B (zh) 2018-09-18 2024-10-29 奥加诺沃公司 法尼醇x受体激动剂及其用途
HU231223B1 (hu) 2018-09-28 2022-01-28 Richter Gedeon Nyrt. GABAA A5 receptor modulátor hatású biciklusos vegyületek
PT3911647T (pt) * 2019-01-15 2024-03-04 Gilead Sciences Inc Composto de isoxazole como agonista de fxr e composições farmacêuticas que o contenham
US12479816B2 (en) 2019-02-08 2025-11-25 University of Pittsburgh—of the Commonwealth System of Higher Education 20-HETE formation inhibitors
KR20210129684A (ko) 2019-02-15 2021-10-28 브리스톨-마이어스 스큅 컴퍼니 파르네소이드 x 수용체 조정제로서 유용한 치환된 아미드 화합물
AR118050A1 (es) 2019-02-15 2021-09-15 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x
CN113677666A (zh) 2019-02-15 2021-11-19 百时美施贵宝公司 作为类法尼醇x受体调节剂的经取代的双环化合物
CN113677659B (zh) 2019-02-15 2024-09-06 百时美施贵宝公司 可用作类法尼醇x受体调节剂的经取代的酰胺化合物
JP2022519906A (ja) 2019-02-19 2022-03-25 ギリアード サイエンシーズ， インコーポレイテッド Ｆｘｒアゴニストの固体形態
JP7697885B2 (ja) * 2019-03-11 2025-06-24 ギリアード サイエンシーズ， インコーポレイテッド 化合物の製剤およびそれらの使用
WO2020231917A1 (en) 2019-05-13 2020-11-19 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
TWI770527B (zh) 2019-06-14 2022-07-11 美商基利科學股份有限公司 Cot 調節劑及其使用方法
EP3999101A1 (en) 2019-07-18 2022-05-25 ENYO Pharma Method for decreasing adverse-effects of interferon
US20230105984A1 (en) 2019-12-23 2023-04-06 Svetlana Marukian Compositions and methods for the treatment of liver diseases and disorders
WO2021144330A1 (en) 2020-01-15 2021-07-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of fxr agonists for treating an infection by hepatitis d virus
CN120732854A (zh) * 2020-03-18 2025-10-03 伊莱利利公司 用于治疗疾病的法尼醇x受体激动剂
IL296532A (en) 2020-03-18 2022-11-01 Metacrine Inc Crystal forms of farnesoid x receptor agonist
WO2021188695A1 (en) 2020-03-18 2021-09-23 Metacrine, Inc. Formulations of a farnesoid x receptor agonist
EP4126858B1 (en) 2020-03-26 2026-03-18 Richter Gedeon Nyrt. Dihydro-2-pyrrolo[3,4-c]pyridine derivatives as gabaa a5 receptor modulators
CA3175541A1 (en) 2020-03-30 2021-10-07 Gilead Sciences, Inc. Solid forms of (s)-6-(((1-(bicyclo[1.1.1]pentan-1-yl)-1h-1,2,3-triazol-4-yl)2-methyl-1-oxo-1,2- dihydroisoquinolin-5-yl)methyl)))amino)8-chloro-(neopentylamino)quinoline-3-carb onitrile a cot inhibitor compound
JP7446475B2 (ja) 2020-04-02 2024-03-08 ギリアード サイエンシーズ， インコーポレイテッド Ｃｏｔ阻害剤化合物を調製するためのプロセス
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
CN114656460B (zh) * 2020-12-22 2025-01-10 江苏天士力帝益药业有限公司 一种新型吡嗪结构fxr激动剂、制备方法及应用
KR20230154806A (ko) 2021-01-14 2023-11-09 엔요 파마 Hbv 감염 치료를 위한 fxr 작용제 및 ifn의 상승작용효과
WO2022192428A1 (en) 2021-03-11 2022-09-15 Gilead Sciences, Inc. Glp-1r modulating compounds
EP4681774A3 (en) 2021-03-29 2026-03-25 Gilead Sciences, Inc. Khk inhibitors
CN117320722A (zh) 2021-04-28 2023-12-29 埃尼奥制药公司 使用fxr激动剂作为联合治疗强烈增强tlr3激动剂的作用
TW202345826A (zh) 2021-06-04 2023-12-01 美商基利科學股份有限公司 治療nash之方法
AU2022291768A1 (en) 2021-06-16 2023-11-30 Celgene Corporation Azetidinyl compounds comprising a carboxylic acid group for the treatment of neurodegenerative diseases
TW202311256A (zh) 2021-06-18 2023-03-16 美商基利科學股份有限公司 用於治療ｆｘｒ誘發之搔癢之ｉｌ－３１調節劑
WO2023125904A1 (zh) * 2021-12-30 2023-07-06 苏州晶云药物科技股份有限公司 氮杂环丁基烟酸类化合物的晶型及其制备方法
WO2024089582A1 (en) 2022-10-25 2024-05-02 Assia Chemical Industries Ltd. Solid state forms of cilofexor salts

Family Cites Families (186)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ193011A (en) 1979-03-19 1983-03-15 Ici Australia Ltd Diarylamine derivatives intermediates herbicidal compositions
DE3880544D1 (de) 1987-04-21 1993-06-03 Basf Ag P-phenoxy-phenoxymethyl-fuenfring-heteroaromaten.
JP3121061B2 (ja) 1991-10-04 2000-12-25 塩野義製薬株式会社 アルコキシイミノアセトアミド類製造用中間体の製造法およびそれに用いる中間体
DE4137940A1 (de) 1991-11-18 1993-05-19 Basf Ag 3-isoxazolylphenylverbindungen, ihre herstellung und ihre verwendung
US5258551A (en) 1991-12-18 1993-11-02 Shionogi & Co., Ltd. Process for producing α-ketoamide derivative
WO1994017059A1 (fr) 1993-01-29 1994-08-04 Nippon Soda Co., Ltd. Derive heterocyclique
WO1994024095A1 (en) 1993-04-16 1994-10-27 Abbott Laboratories Immunosuppressive agents
IL112721A0 (en) 1994-03-10 1995-05-26 Zeneca Ltd Azole derivatives
CA2195107A1 (en) 1994-08-02 1996-02-15 Richard Alexander Jelley Azetidine, pyrrolidine and piperidine derivatives
GB9501865D0 (en) 1995-01-31 1995-03-22 Merck Sharp & Dohme Therapeutic agents
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
DE19536811A1 (de) 1995-10-02 1997-04-03 Basf Ag Zwischenprodukte und Verfahren zur Herstellung von substituierten Salicylsäurederivaten als Pflanzenschutzmittel
DK0880363T3 (da) 1996-02-13 2003-01-20 Searle & Co Kombinationer der omfatter en cyclooxygenase-2 hæmmer samt en leukotrien A4 hydrolasehæmmer, som har immunsuppressive virkninger
JP2002532729A (ja) 1998-12-23 2002-10-02 グラクソ グループ リミテッド 核内受容体のリガンドのアッセイ
HK1047752A1 (zh) 1999-06-11 2003-03-07 Allergan, Inc. 具有核激素受体调节活性的有机硅化合物
EP1340749A4 (en) 2000-11-17 2007-09-05 Takeda Pharmaceutical ISOXAZOLE DERIVATIVES
US20040105883A1 (en) 2001-04-17 2004-06-03 Ping Gao Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage
US20040105884A1 (en) 2001-04-17 2004-06-03 Ping Gao Pharmaceutical dosage form comprising a sulfite compound
US20040131670A1 (en) 2001-04-17 2004-07-08 Ping Gao Pellicle-resistant gelatin capsule
US20040105885A1 (en) 2001-04-17 2004-06-03 Ping Gao Gelatin capsule exhibiting reduced cross-linking
EP1405636A4 (en) 2001-06-26 2009-04-15 Takeda Pharmaceutical FUNCTIONAL REGULATOR FOR RETINOID RELATIVE RECEPTOR
ATE381542T1 (de) 2001-08-13 2008-01-15 Phenex Pharmaceuticals Ag Nr1h4-kern-rezeptor-bindende verbindungen
WO2003016280A1 (en) 2001-08-13 2003-02-27 Lion Bioscience Ag Nr1h4 nuclear receptor binding compounds
EP1423113A4 (en) 2001-08-13 2007-04-18 Phenex Pharmaceuticals Ag NR1H4 NUCLEAR RECEPTOR BINDING COMPOUNDS
WO2003080803A2 (en) 2002-03-21 2003-10-02 Smithkline Beecham Corporation Methods of using farnesoid x receptor (fxr) agonists
US7595311B2 (en) 2002-05-24 2009-09-29 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
US7074809B2 (en) 2002-08-09 2006-07-11 Astrazeneca Ab Compounds
TW200424183A (en) 2002-08-09 2004-11-16 Nps Pharma Inc New compounds
WO2004014881A2 (en) 2002-08-09 2004-02-19 Astra Zeneca Ab '1,2,4'oxadiazoles as modulators of metabotropic glutamate receptor-5
EP1407774A1 (en) 2002-09-10 2004-04-14 LION Bioscience AG 2-Amino-4-quinazolinones as LXR nuclear receptor binding compounds
AU2003290796A1 (en) 2002-11-14 2004-06-15 The Scripps Research Institute Non-steroidal fxr agonists
US20050143449A1 (en) 2002-11-15 2005-06-30 The Salk Institute For Biological Studies Non-steroidal farnesoid X receptor modulators and methods for the use thereof
JP2006515838A (ja) 2002-11-22 2006-06-08 スミスクライン ビーチャム コーポレーション ファルネソイドｘ受容体アゴニスト
US20070166710A1 (en) 2003-03-31 2007-07-19 Markus Stoffel Methods for inhibiting adipogenesis and for treating type 2 diabetes
WO2005077345A1 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Compounds for the treatment of gastro-esophageal reflux disease
WO2005077373A2 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
US7585881B2 (en) 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
WO2005113519A1 (en) 2004-05-14 2005-12-01 Irm Llc Compounds and compositions as ppar modulators
MY144903A (en) 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists
EP2402323A3 (en) 2004-10-13 2012-05-30 PTC Therapeutics, Inc. Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases
JP2008137894A (ja) 2005-03-22 2008-06-19 Nippon Kayaku Co Ltd 新規なアセチレン誘導体
TW200716576A (en) 2005-06-07 2007-05-01 Shionogi & Co Heterocyclic derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
EP1963331A1 (en) 2005-12-15 2008-09-03 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
JP5081161B2 (ja) 2005-12-19 2012-11-21 スミスクライン ビーチャム コーポレーション ファルネソイドｘ受容体アゴニスト
US7560551B2 (en) 2006-01-23 2009-07-14 Amgen Inc. Aurora kinase modulators and method of use
CA2640476A1 (en) 2006-02-03 2007-08-16 Eli Lilly And Company Compounds and methods for modulating fx-receptors
JP2010517931A (ja) * 2006-02-14 2010-05-27 インターセプト ファーマシューティカルズ， インコーポレイテッド Ｆｘｒ媒介性の疾患または状態の予防または治療用のｆｘｒリガンドとしての胆汁酸誘導体
CA2643924A1 (en) 2006-04-17 2007-10-25 Neuromed Pharmaceuticals Ltd. Isoxazole derivatives as calcium channel blockers
US8106077B2 (en) 2006-05-24 2012-01-31 Eli Lilly And Company Compounds and methods for modulating FXR
EP2029600B1 (de) 2006-05-24 2012-03-14 Boehringer Ingelheim International GmbH Substituierte pteridine, die mit einem viergliedrigen heterocyclus substituiert sind
BRPI0712262A2 (pt) 2006-05-24 2012-07-10 Lilly Co Eli agonistas de fxr
CN101448798A (zh) * 2006-05-24 2009-06-03 伊莱利利公司 用于调节fxr的化合物和方法
PT2040713E (pt) 2006-06-27 2014-10-13 Intercept Pharmaceuticals Inc Para a prevenção ou o tratamento de doenças ou estados clínicos mediados por fxr
EP2043651A2 (en) 2006-07-05 2009-04-08 Exelixis, Inc. Methods of using igf1r and abl kinase modulators
CN101501023A (zh) 2006-07-07 2009-08-05 贝林格尔.英格海姆国际有限公司 苯基取代的杂芳基衍生物及其作为抗肿瘤剂的用途
US20080032990A1 (en) 2006-07-07 2008-02-07 Khalifah Raja G Inhibitors of advanced glycation end products
EP1894928A1 (en) 2006-08-29 2008-03-05 PheneX Pharmaceuticals AG Heterocyclic fxr binding compounds
EP1894924A1 (en) * 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
US8193225B2 (en) 2006-10-13 2012-06-05 The Board Of Regents Of The University Of Texas System Isoxazole amides, derivatives and methods of chemical induction of neurogenesis
CL2007003035A1 (es) 2006-10-24 2008-05-16 Smithkline Beechman Corp Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos,
US8501933B2 (en) 2006-11-09 2013-08-06 Roche Palo Alto Llc Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists
KR20090094125A (ko) 2006-12-08 2009-09-03 엑셀리시스, 인코포레이티드 Ｌｘｒ 및 ｆｘｒ 조절자
GB0625842D0 (en) 2006-12-22 2007-02-07 Argenta Discovery Ltd Indolizine derivatives
US20090105251A1 (en) 2007-01-25 2009-04-23 Benjamin Jones Renin inhibitors
WO2008097235A1 (en) 2007-02-09 2008-08-14 Dow Agrosciences Llc Process for the oxidation of certain substituted sulfilimines to insecticidal sulfoximines
US7511149B2 (en) 2007-02-09 2009-03-31 Dow Agrosciences Llc Process for the oxidation of certain substituted sulfilimines to insecticidal sulfoximines
US7868027B2 (en) 2007-02-26 2011-01-11 Dow Agrosciences Llc Process for the preparation of certain substituted sulfilimines
WO2008157270A1 (en) 2007-06-13 2008-12-24 Smithkline Beecham Corporation Farnesoid x receptor agonists
JP2008308448A (ja) 2007-06-15 2008-12-25 Sankyo Agro Kk （３−硫黄原子置換フェニル）へテロアリール誘導体
WO2008155054A1 (en) 2007-06-20 2008-12-24 F. Hoffmann-La Roche Ag Farnesoid-x-receptor mutants, and crystallisation thereof
CA2692379A1 (en) 2007-07-02 2009-01-08 Boehringer Ingelheim International Gmbh Antiproliferative compounds based on 5-membered heterocycles
CA2690406A1 (en) 2007-07-02 2009-01-08 Glaxosmithkline Llc Farnesoid x receptor agonists
EP2178877A1 (en) 2007-07-13 2010-04-28 GlaxoSmithKline LLC Anti-viral compounds, compositions, and methods of use
US20090197880A1 (en) 2007-07-13 2009-08-06 Genelabs Technologies, Inc. Anti-viral compounds, compositions, and methods of use
TW200906823A (en) 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
AR070513A1 (es) 2007-08-01 2010-04-14 Lundbeck & Co As H Uso de abridores de canales de potasio kcnq para reducir los sintomas o tratar desordenes o afecciones en las cuales se encuentra anulado el sis-tema dopaminergico como por ejemplo esquizofrenia y trastorno depresivo mayor
US8188080B2 (en) 2007-10-17 2012-05-29 Sanford-Burnham Medical Research Institute VHR protein tyrosine phosphatase inhibitors, compositions and methods of use
US20090143451A1 (en) 2007-11-14 2009-06-04 Andrews William H Compounds that increase telomerase reverse transcriptase (tert) expression and methods for using the same
EP2110374A1 (en) 2008-04-18 2009-10-21 Merck Sante Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
EP2418207A1 (en) 2008-05-13 2012-02-15 Boehringer Ingelheim International GmbH Sulfone compounds which modulate the CB2 receptor
JP2011521916A (ja) 2008-05-19 2011-07-28 バーナム インスティテュート フォー メディカル リサーチ 腸アルカリホスファターゼモジュレーターおよびそれの使用
WO2009143018A2 (en) 2008-05-19 2009-11-26 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
EP2128158A1 (en) 2008-05-26 2009-12-02 Phenex Pharmaceuticals AG Heterocyclic cyclopropyl-substituted FXR binding compounds
JP5767965B2 (ja) 2008-06-10 2015-08-26 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． キナーゼを調節する５ｈ−ピロロ［２，３−ｂ］ピラジン誘導体、およびその適応症
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
EP2307370B1 (en) 2008-06-23 2012-01-04 Basf Se Sulfoximinamide compounds for combating animal pests
US20100029655A1 (en) 2008-07-11 2010-02-04 Martin Robert Leivers Processes For The Preparation Of Anti-Viral Compounds And Compositions Containing Them
US8044214B2 (en) 2008-08-25 2011-10-25 Angus Chemical Company Process for preparing isoxazole compounds
US20120021519A1 (en) 2008-09-19 2012-01-26 Presidents And Fellows Of Harvard College Efficient induction of pluripotent stem cells using small molecule compounds
JP5450632B2 (ja) 2008-09-25 2014-03-26 エフ．ホフマン−ラ ロシュ アーゲー ３−アミノ−インダゾール又は３−アミノ−４，５，６，７−テトラヒドロインダゾール誘導体
CA2735886A1 (en) 2008-09-25 2010-04-01 F. Hoffmann-La Roche Ag Indazole or 4,5,6,7-tetrahydro-indazole derivatives
CA2736880A1 (en) 2008-09-26 2010-04-01 Wyeth Llc 1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate nuclear receptor inhibitors
EA022417B1 (ru) 2008-10-21 2015-12-30 Саймабэй Терапевтикс, Инк. Арильные агонисты рецептора gpr120 и их применение
JP5679997B2 (ja) 2009-02-04 2015-03-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状阻害剤
KR20100092909A (ko) 2009-02-13 2010-08-23 주식회사 엘지생명과학 잔틴 옥시다제 저해제로서 효과적인 신규 화합물, 그 제조방법 및 그를 함유하는 약제학적 조성물
FR2943059A1 (fr) 2009-03-16 2010-09-17 Sanofi Aventis Derives de n-°6-aza-bicyclo°3.2.1!oct-5-yl)-aryl-methyl!- heterobenzamide,leur preparation et leur application en therapeutique
US8883832B2 (en) 2009-07-06 2014-11-11 Aerpio Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
ES2461618T3 (es) 2009-07-06 2014-05-20 Basf Se Compuestos de piridacina para el control de plagas de invertebrados
JP2013500246A (ja) 2009-07-24 2013-01-07 ビーエーエスエフ ソシエタス・ヨーロピア 無脊椎動物系害虫防除用ピリジン誘導体化合物
US9212177B2 (en) 2009-08-05 2015-12-15 Versitech Limited Antiviral compounds and methods of making and using thereof
EP2289883A1 (en) 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
AU2010291834A1 (en) 2009-09-04 2012-03-15 Zalicus Pharmaceuticals Ltd. Substituted heterocyclic derivatives for the treatment of pain and epilepsy
US9095596B2 (en) 2009-10-15 2015-08-04 Southern Research Institute Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such
JP5879273B2 (ja) 2010-03-01 2016-03-08 ジーティーエックス・インコーポレイテッド 癌を処置するための化合物
EP2580213A4 (en) 2010-06-09 2013-12-25 Afraxis Holdings Inc 8- (HETEROARYLMETHYL) PYRIDO [2,3-D] PYRIMIDIN-7 (8H) -ONES FOR THE TREATMENT OF CNS DISORDERS
WO2012058531A2 (en) 2010-10-29 2012-05-03 North Carolina State University Modulation of response regulators by imidazole derivatives
TWI408128B (zh) 2010-12-03 2013-09-11 Nat Univ Tsing Hua 間-三聯苯衍生物及其在有機發光二極體之應用
JP2014500319A (ja) 2010-12-20 2014-01-09 アイアールエム・リミテッド・ライアビリティ・カンパニー ファルネソイドｘ受容体を調節するための組成物および方法
CU24152B1 (es) 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
WO2012087520A1 (en) 2010-12-20 2012-06-28 Irm Llc Compositions and methods for modulating farnesoid x receptors
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
WO2013037482A1 (en) 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
NZ734451A (en) 2012-06-19 2018-12-21 Intercept Pharmaceuticals Inc Preparation, uses and solid forms of obeticholic acid
TWI621618B (zh) 2013-03-13 2018-04-21 比利時商健生藥品公司 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途
WO2014181287A1 (en) 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
CA2912139C (en) 2013-05-14 2021-04-20 Roberto Pellicciari 11-hydroxyl-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators
JP6556129B2 (ja) 2013-08-01 2019-08-07 アメリカ合衆国 ファルネソイドｘ受容体の阻害剤及び医薬としての使用
SI3043865T1 (sl) 2013-09-11 2021-04-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Metode in farmacevtski sestavki za zdravljenje virusne okužbe s hepatitisom B
US20150082981A1 (en) 2013-09-20 2015-03-26 E I Du Pont De Nemours And Company Capture of trifluoromethane using ionic liquids
CN104513213A (zh) 2013-09-28 2015-04-15 山东亨利医药科技有限责任公司 Fxr激动剂
WO2015065983A1 (en) 2013-10-29 2015-05-07 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of gastrointestinal infections
KR102350357B1 (ko) 2013-11-05 2022-01-14 노파르티스 아게 파르네소이드 x 수용체의 조정을 위한 조성물 및 방법
WO2015116856A2 (en) 2014-01-29 2015-08-06 City Of Hope Farnesoid x receptor antagonists
EP3116878A4 (en) 2014-03-13 2018-02-14 Salk Institute for Biological Studies Fxr agonists and methods for making and using
US10077268B2 (en) 2014-03-13 2018-09-18 Salk Institute For Biological Studies FXR agonists and methods for making and using
AU2015229055B2 (en) 2014-03-13 2019-09-12 Salk Institute For Biological Studies Analogs of fexaramine and methods of making and using
EP3495360A1 (en) 2014-04-14 2019-06-12 Grünenthal GmbH Heteroaryl substituted heterocyclyl sulfones
WO2015162538A1 (en) 2014-04-21 2015-10-29 Lupin Limited Heterocyclic compounds as calcium sensing receptor modulators for the treatment of hyperparathyroidism, chronic renal failure and chronic kidney disease
WO2015162244A1 (en) 2014-04-25 2015-10-29 Basf Se N-acylamidine compounds
WO2015165960A1 (en) 2014-04-30 2015-11-05 Basf Se N-acylamidine compounds
US10407462B2 (en) 2014-05-29 2019-09-10 Bar Pharmaceuticals S.R.L. Cholane derivatives for use in the treatment and/or prevention of FXR and TGR5/GPBAR1 mediated diseases
CN104045635A (zh) 2014-06-23 2014-09-17 华东理工大学 3,4,5-三取代异恶唑类化合物及其用途
WO2016054560A1 (en) 2014-10-02 2016-04-07 Flatley Discovery Lab Isoxazole compounds and methods for the treatment of cystic fibrosis
EP3006939A1 (en) 2014-10-06 2016-04-13 Gilead Sciences, Inc. Histidine-rich Glycoprotein as a marker for hepatic Farnesoid X receptor activation
CN106716665B9 (zh) 2014-10-27 2018-12-07 株式会社Lg化学 有机电致发光器件
WO2016073767A1 (en) 2014-11-06 2016-05-12 Enanta Pharmaceuticals, Inc. Bile acid analogs an fxr/tgr5 agonists and methods of use thereof
CN111662297A (zh) 2014-11-21 2020-09-15 阿卡纳治疗学有限公司 用于治疗疾病的稠合双环化合物
JP2017535570A (ja) 2014-11-26 2017-11-30 エナンタ ファーマシューティカルズ インコーポレイテッド Ｆｘｒ／ｔｇｒ５アゴニストとしての胆汁酸類似体およびその使用方法
WO2016086134A1 (en) 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
US11578097B2 (en) 2014-11-26 2023-02-14 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
EP3034501A1 (en) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Hydroxy containing FXR (NR1H4) modulating compounds
EP3034499A1 (en) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Novel FXR (NR1H4) modulating compounds
US20170368038A1 (en) 2014-12-18 2017-12-28 Novartis Ag Azabicyclooctane derivatives as fxr agonists for use in the treatment of liver and gastrointestinal diseases
EA201791258A1 (ru) 2015-01-09 2017-12-29 Джилид Аполло, Ллс Комбинированная терапия с применением ингибитора ацетил-коа-карбоксилазы (acc) для лечения неалкогольной жировой болезни печени
NZ734082A (en) 2015-01-20 2019-01-25 Boehringer Ingelheim Animal Health Usa Inc Anthelmintic compounds, compositions and method of using thereof
TWI698430B (zh) 2015-02-13 2020-07-11 南北兄弟藥業投資有限公司 三環化合物及其在藥物中的應用
US10100285B2 (en) 2015-04-03 2018-10-16 Propagenix Inc. Ex vivo proliferation of epithelial cells
CN106146483A (zh) 2015-04-23 2016-11-23 上海迪诺医药科技有限公司 杂环类法尼酯衍生物x受体调节剂
GB201507340D0 (en) 2015-04-29 2015-06-10 Univ St Andrews Light emitting devices and compounds
ES2550374B1 (es) * 2015-06-30 2016-09-08 Universidad De La Rioja Compuestos fotoprotectores análogos de MAA, procedimiento de síntesis y composición que comprende los mismos
WO2017011466A1 (en) 2015-07-13 2017-01-19 Zwiebel Laurence J Thermal volatilization of orco agonists
WO2017044454A1 (en) 2015-09-11 2017-03-16 Propagenix Inc. Ex vivo proliferation of epithelial cells
EP3383860B1 (en) 2015-12-04 2021-01-20 Bristol-Myers Squibb Company Apelin receptor agonists and methods of use
TW201734002A (zh) 2015-12-11 2017-10-01 拜耳作物科學股份有限公司 作為殺蟲劑之經取代的丙二醯胺類
CN106946867B (zh) 2016-01-06 2019-11-12 广州市恒诺康医药科技有限公司 Fxr受体调节剂及其制备方法和用途
EP3190103A1 (en) 2016-01-08 2017-07-12 Rijksuniversiteit Groningen Inhibitors of the pd-1/pd-l1 protein/protein interaction
EP3400229B1 (en) 2016-01-10 2024-03-06 Provincial Health Services Authority 18/19f-labelled compounds which target the prostate specific membrane antigen
WO2017122209A2 (en) 2016-01-12 2017-07-20 Yeda Research And Development Co. Ltd. NF-kappaB INHIBITORS
WO2017128896A1 (zh) 2016-01-26 2017-08-03 江苏豪森药业集团有限公司 Fxr激动剂及其制备方法和应用
WO2017133521A1 (zh) 2016-02-01 2017-08-10 山东轩竹医药科技有限公司 Fxr受体激动剂
CN107021958A (zh) 2016-02-01 2017-08-08 山东轩竹医药科技有限公司 Fxr受体激动剂
CN107021957A (zh) 2016-02-01 2017-08-08 山东轩竹医药科技有限公司 Fxr受体激动剂
TW201741307A (zh) 2016-02-22 2017-12-01 艾洛斯生物製藥公司 Ｆｘｒ調節劑及其使用方法
CN107224583A (zh) 2016-03-24 2017-10-03 中美华世通生物医药科技（武汉）有限公司 药物组合物及其用途
US10080741B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
WO2017189651A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
WO2017189663A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
WO2017201152A1 (en) 2016-05-18 2017-11-23 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
WO2017201155A1 (en) 2016-05-18 2017-11-23 Enanta Pharmaceuticals, Inc. lSOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF
US10144729B2 (en) 2016-05-18 2018-12-04 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
JP2019517523A (ja) 2016-06-03 2019-06-24 ケモセントリックス， インコーポレイテッド 肝線維症を治療する方法
CA2968836C (en) 2016-06-13 2025-09-02 Gilead Sciences, Inc. FXR MODULATING COMPOUNDS (NR1H4)
NZ748641A (en) 2016-06-13 2020-04-24 Gilead Sciences Inc Fxr (nr1h4) modulating compounds
TW201808283A (zh) 2016-08-05 2018-03-16 廣東東陽光藥業有限公司 含氮三環化合物及其在藥物中的應用
MA55632A (fr) 2016-08-23 2022-02-16 Ardelyx Inc Procédé de preparation de modulateurs du récepteur hormonal pour le traitement d'états et de troubles métaboliques
US11091482B2 (en) 2016-08-23 2021-08-17 Ardelyx, Inc. Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators
CN108430998B (zh) 2016-09-28 2021-07-09 四川科伦博泰生物医药股份有限公司 氮杂双环衍生物及其制备方法和用途
CN109983010A (zh) 2016-09-29 2019-07-05 拜耳作物科学股份公司 作为用于作物保护的杀真菌剂的1-[2-(1-氯环丙基)-2-羟基-3-(3-苯基-1,2-噁唑-5-基)丙基]-1h-咪唑-5-甲腈衍生物及相关化合物
MX2019003790A (es) 2016-10-04 2019-09-26 Enanta Pharm Inc Analogos de isoxazol como agonistas de fxr y metodos de uso de los mismos.
CN107973790A (zh) 2016-10-22 2018-05-01 合帕吉恩治疗公司 杂环fxr调节剂
CA3043284C (en) 2016-11-10 2022-06-28 Galmed Research And Development Ltd. Treatment for fibrosis
CA3042398A1 (en) 2016-11-11 2018-05-17 Gilead Sciences, Inc. Methods of treating liver disease
CN106588804B (zh) 2016-12-09 2018-11-09 都创(上海)医药科技有限公司 一种作为类法尼醇x受体(fxr)的化合物的制备方法
CN106632294A (zh) 2016-12-15 2017-05-10 宁波百纳西药业有限公司 一种螺环化合物及其药物用途
CN106748922B (zh) 2017-01-12 2019-02-01 中国药科大学 一类新型砜酸衍生物、其制备方法及其作为药物的用途

Also Published As

Publication number Publication date
US20190142814A1 (en) 2019-05-16
JP2017014249A (ja) 2017-01-19
DK3246070T3 (da) 2024-04-02
HUE066734T2 (hu) 2024-09-28
US9539244B2 (en) 2017-01-10
WO2013007387A1 (en) 2013-01-17
DK2731676T3 (en) 2016-05-02
US9820979B2 (en) 2017-11-21
MX2019011629A (es) 2019-12-05
RS54786B1 (sr) 2016-10-31
CA2839357A1 (en) 2013-01-17
EA201391674A1 (ru) 2014-08-29
HUE027931T2 (en) 2016-11-28
ZA201309521B (en) 2014-08-27
KR20170093258A (ko) 2017-08-14
HRP20160442T1 (hr) 2016-05-20
EP2731676A1 (en) 2014-05-21
BR122019026062B1 (pt) 2020-12-15
MX368371B (es) 2019-09-30
AU2016265993A1 (en) 2016-12-15
KR20180053771A (ko) 2018-05-23
TW201302719A (zh) 2013-01-16
CN103702719A (zh) 2014-04-02
UY34196A (es) 2013-01-31
PT3246070T (pt) 2024-05-15
ES2569718T3 (es) 2016-05-12
EP4400503A2 (en) 2024-07-17
BR122020008872B1 (pt) 2022-04-12
CN103702719B (zh) 2017-09-08
US10220027B2 (en) 2019-03-05
MX2014000534A (es) 2014-05-13
SMT201600169B (it) 2016-07-01
AU2012283387B2 (en) 2016-09-08
CN107252424B (zh) 2020-03-27
AU2012283387C1 (en) 2020-03-12
KR101766323B1 (ko) 2017-08-08
JP2014520823A (ja) 2014-08-25
AU2016265993B2 (en) 2018-03-15
KR101722410B1 (ko) 2017-04-03
CA2839357C (en) 2017-10-24
AR087127A1 (es) 2014-02-12
EP2731676B1 (en) 2016-02-03
HK1221680A1 (en) 2017-06-09
JP5986633B2 (ja) 2016-09-06
EP4400503A3 (en) 2024-10-23
SI2731676T1 (sl) 2016-06-30
AU2018203613A1 (en) 2018-06-14
US20180200243A1 (en) 2018-07-19
EP2987532B1 (en) 2017-04-12
PH12014500124A1 (en) 2015-09-23
KR101859533B1 (ko) 2018-05-18
TWI439455B (zh) 2014-06-01
CY1117453T1 (el) 2017-04-26
EA024843B1 (ru) 2016-10-31
AU2012283387A1 (en) 2014-01-09
MY161158A (en) 2017-04-14
EP3246070A1 (en) 2017-11-22
SI3246070T1 (sl) 2024-05-31
IL229944A (en) 2017-07-31
CN107252424A (zh) 2017-10-17
HK1192181A1 (zh) 2014-08-15
BR112014000260B1 (pt) 2020-08-11
EP3246070B1 (en) 2024-03-20
ES2978166T3 (es) 2024-09-06
US20170143684A1 (en) 2017-05-25
HRP20240422T1 (hr) 2024-06-21
ES2632492T3 (es) 2017-09-13
PT2987532T (pt) 2017-07-13
BR112014000260A2 (pt) 2017-03-01
AU2019261667A1 (en) 2019-11-28
KR101934335B1 (ko) 2019-01-02
LT3246070T (lt) 2024-04-25
JP6321097B2 (ja) 2018-05-09
US10485795B2 (en) 2019-11-26
US20150342930A1 (en) 2015-12-03
NZ710770A (en) 2017-02-24
EP2545964A1 (en) 2013-01-16
AU2019261667B2 (en) 2021-03-11
US9139539B2 (en) 2015-09-22
AU2018203613B2 (en) 2019-08-08
SI2987532T1 (sl) 2017-07-31
PL2731676T3 (pl) 2016-08-31
PL3246070T3 (pl) 2024-08-05
KR20170007543A (ko) 2017-01-18
US20140221659A1 (en) 2014-08-07
FI3246070T3 (fi) 2024-04-18
KR20140051932A (ko) 2014-05-02
NZ620177A (en) 2015-10-30
EP2987532A1 (en) 2016-02-24
PL2987532T3 (pl) 2017-10-31

Similar Documents

Publication Publication Date Title
ME02434B (me) Nova jedinjenja koja moduliraju fxr (nr1h4)
JP2014520823A5 (me)
ME02047B (me) Nova jedinjenja koja se vezuju za fxr (nr1 h4) i moduliraju njegovu aktivnost
HRP20191561T1 (hr) Spojevi za modulaciju fxr (nr1h4)
HRP20240265T1 (hr) Spoj izoksazola kao fxr agonist i farmaceutski pripravci koji ga sadrže
JP6452821B2 (ja) 新規なｆｘｒ（ｎｒ１ｈ４）モジュレート化合物
CA2885969C (en) Substitued pyridine derivatives and compositions thereof useful as inhibitors of histone demethylases
ES2538655T3 (es) 3-Amino-piridinas como agonistas de GPBAR1
CN114728168A (zh) 三唑氨基甲酸酯吡啶基磺酰胺作为lpa受体拮抗剂及其用途
RU2015137659A (ru) Композиции и способы для лечения хронического воспаления и воспалительных заболеваний
HRP20241656T1 (hr) Derivat nitrila koji djeluje kao inhibitor dipeptidil peptidaze 1 i njegova upotreba
CN112955448A (zh) 芳环或芳杂环类化合物及其制备方法和医药用途
CA2716352A1 (en) Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders
JP2019521977A (ja) Ｆｘｒ（ｎｒ１ｈ４）調節化合物
JP2016517432A5 (me)
JP2011511046A (ja) ５，６−ビスアリール−２−ピリジン−カルボキシアミド誘導体、この調製、およびウロテンシンｉｉ受容体の拮抗剤としてのこの治療的用途
KR102796877B1 (ko) 신규 ep4 길항제의 합성 및 암과 염증에서의 이의 용도
JP2013501031A5 (me)
WO2013040790A1 (en) Substituted pyrimidines
KR20190112009A (ko) Ror감마 조절제 및 이의 용도
WO2013043624A1 (en) Substituted pyrimidines
JP2009522377A5 (me)
CN116615193A (zh) 作为选择性fabp5抑制剂的吐昔酸单酯衍生物和药物组合物及其用途
CN116056706B (zh) 可用作二酰基甘油酰基转移酶2抑制剂的联芳基衍生物及其用途
JP2013532682A5 (me)